Council Report
AVMA Council on Biologic and
Therapeutic Agents’ report on cat and dog vaccines
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Donald J. Klingborg, DVM; David R. Hustead, DVM;
Elizabeth A. Curry-Galvin, DVM; Nigel R. Gumley, DVM, DABVP; Steven C.
Henry, DVM, DABVP; Fairfield T. Bain, DVM, DACVIM, DACVP, DACVECC; Michael
A. Paul, DVM; Dawn M. Boothe, DVM, PhD, DACVIM, DACVCP; K. Shawn Blood,
DVM; David L. Huxsoll, DVM, PhD; Donald L. Reynolds, DVM, PhD, DACVM; M.
Gatz Riddell Jr, MS, DVM, DACT; James S. Reid, VMD, DABVP; Charles R.
Short, DVM, PhD, DACVCP
* |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The AVMA Council
on Biologic and Therapeutic Agents (COBTA) has undertaken a comprehensive review of dog and
cat vaccination information. This process included review of the published
literature, as well as convening 4 panels of experts to form a consensus
on use of canine and feline vaccines. The 4 panels included experts from
academic, industry, regulatory, and practice backgrounds. This
report represents the fifth of 6 or more steps in the process of
communicating to the profession. Step 1 was a Commentary article prepared
by COBTA titled "Vaccination issues of concern to practitioners"
published in the April 1, 1999 JAVMA. Step 2 was the open
practitioner forum held during the 2000 AVMA Annual Convention in Salt
Lake City. Step 3 was the release of the Principles of Vaccination. Step 4
was the redrafting of the AVMA client information brochure titled
"What you should know about vaccination." Vaccine Issues for Practitioners Almost
every veterinary practitioner has experienced the devastating impacts of
diseases of dogs and cats that can now be prevented with effective
vaccination. Vaccination programs have played an important role in
preventing diseases and in fostering early detection and treatment through
regular physical examinations during the life of the animal. Historically,
when any doubt existed regarding the need to vaccinate an animal,
practitioners usually recommended revaccination. They strove to provide
maximum protection for the animal, because the risks associated with
vaccination were considered minimal compared with the threat of disease.
Veterinarians' experiences with the value of vaccines in preventing
disease morbidity and mortality, coupled with the inability to quantify
risks associated with vaccination, prompted the vaccination rates commonly
accepted under the standard of veterinary care until recently. Vaccination
recommendations used to be considered a simple part of animal care, but
are now considered complex and controversial. Currently, recommendations
tend to reflect what has always been true—vaccination is the complex use
of medically powerful agents for which important medical decisions on
relative risks and benefits must be individualized to the needs of the
animal. Summary of the Principles of Vaccination The
AVMA, through COBTA and other contributors, has collected valid scientific
information on the subject and kept practitioners informed of these
findings. Because of these actions, the AVMA Executive Board approved
COBTA's Principles of Vaccination in April 2001. Practitioners can find
the principles in the September 1, 2001 issue of the JAVMA or on
the AVMA Web site (www.avma.org). In addition, a copy of the principles
may be requested from the AVMA office. A
few of the take-home messages from this document include:
Concerns about the Principles of Vaccination By
far, the most common criticism of the principles is that that they do not
tell practitioners how to set up vaccination programs. This is true. The
COBTA determined early in its investigation that the creation of suggested
vaccination protocols was beyond its scope. The council could not write
vaccination protocols that would apply to all species, all animals, in all
animal environments, for all geographic regions, or for all veterinarians.
Therefore, COBTA strove to write a set of principles that would have
universal application for all veterinarians. The council will encourage
those allied organizations, through the Clinical Practitioners Advisory
Committee, to develop more precise vaccination recommendations applying
the principles of vaccination to ensure their recommendations are science
based versus a substitute of one arbitrary standard for another. Current and Future Plans COBTA
has developed a new client education brochure to comply with the
principles of vaccination. The brochure includes discussion of vaccination
issues and concerns. It is designed to aid practitioners' educational
programs for clients by explaining what vaccines are, why vaccines are
needed, how vaccines work, and how they are used in a complete preventive
medicine program. COBTA
is actively working with allied species groups of the AVMA to encourage
science-based, species-specific vaccination information. COBTA
is working with the USDA and the Animal Health Institute (a group
representing vaccine manufacturers) to develop a new set of guidelines for
labeling vaccines. It is the council's goal to create vaccine labels that
accurately identify the product, inform practitioners about what the
vaccine contains, adequately describe the data submitted to the USDA to
support the stated safety and efficacy of the vaccine, accurately describe
pertinent safety issues, and feature claims or use recommendations that
are adequately based in science. The council believes duration of immunity
claims, which should include considerations of minimum and maximum
duration of immunity, are best answered by scientific study and should not
be represented by an arbitrary one-size-fits all label. The
council is working with the entire cross section of the animal health
industry to redefine how safety and efficacy information from the clinical
use of animal health products is gathered, analyzed, and disseminated. An
appropriate system might include a set of sentinel practices in various
geographic locations. Practices in the network would collect information
about infectious diseases in their area and information about animals
after they were exposed to, or treated with, medicinal agents. It is
COBTA's goal to create a system that will accurately provide to
researchers and practitioners clinically relevant information about any
threat that is posed by infectious organisms and to collect information
about the actual clinical use of medicinal agents in animals. Vaccines and Vaccine Handling Vaccine
handling, including shipment and storage, is critical to maintaining
potency to the expiration date. Vaccines are sensitive to extreme heat or
freezing. Every user should have a protocol for immediately checking the
condition of vaccines when they arrive, because vaccines that are too warm
or too cold may be damaged. If a damaged product is received,
veterinarians should immediately record the condition, contact the
company, determine that the returned product will be destroyed, and follow
the company's instructions for return and replacement. Development
of validated methods for proper handling of vaccines during shipment and
storage is needed to ensure the integrity of biologics and the health of
animals. Veterinarians are reminded that the refrigerators they use for
storage of vaccines should have their temperatures checked regularly using
validated methods. Specific Disease and Vaccine Comments Comments
on diseases are offered for the typical house pet cat and dog and do not
consider the special circumstances associated with catteries, kennels,
shelters, or households with numerous animals contained in interactive
environments. A few comments are included on multiple-cat households with
respect to certain diseases; however, readers are cautioned that this
review did not focus on the special circumstances associated with
high-density animal environments. Kittens and puppies under 16 weeks of
age represent the most susceptible age group. They experience the highest
rates and most severe cases of disease and are therefore the principal
target population for vaccination. Maternal antibody is a substantial
impediment to successful immunization against many diseases; therefore, a
series of periodically spaced vaccinations is indicated in young animals. COBTA
supports recommendations that administration sites for potential
injections in cats be chosen according to the guidelines developed by the
American Association of Feline Practitioners and adopted by the
Vaccine-Associated Feline Sarcoma Task Force. To further characterize the
causal link and to facilitate treatment of vaccine-associated sarcomas, it
is recommended that:
Additionally,
veterinarians should document the injection location, vaccine type,
manufacturer, and serial number in the medical record. Injection sites of
other medications should also be recorded. Core Vaccines Vaccines
against the following diseases, caused by pathogens that are widely
distributed in North America and pose a substantial risk of severe disease
in essentially all cats and dogs, should be considered core vaccines. Core Vaccines for
Cats
Vaccines
against feline leukemia virus infection, which is caused by a viral
pathogen widely distributed in North America that may pose a risk of
severe disease, should be considered as an additional core vaccine for all
cats that live outside full or part time, or those living full time inside
but with exposure to outside cats. If recommended, it should target
kittens:
Core Vaccines for
Dogs
Noncore Vaccines The
benefits and risks of using vaccine products against the diseases listed
in the following section must be carefully considered by veterinarians and
owners/clients when 1 or more of the following conditions exist: limited
potential for exposure to the disease because of the animal's lifestyle or
the nonuniform exposure distribution of the disease in North America,
lower virulence of the disease representing less severe illness, vaccine
benefit-risk ratios that are insufficient to warrant the use of these
products in all circumstances, and a lack of adequate scientific
information to evaluate clinical need, efficacy, and safety of the
vaccine. Noncore Vaccines
for Cats
Noncore Vaccines
for Dogs
Vaccine Use Issues One
aspect of the decision to use a vaccine in dogs and cats is assessment of
the benefits of providing some level of vaccine-induced protection against
the disease and the potential risk of adverse events associated with
vaccination. Little unbiased information is available to veterinarians on
the effectiveness and safety of vaccines used in clinical practice
settings. This lack of information is the result of many factors, but 1 of
the more important is an inadequate system for adverse event data capture,
analysis, and dissemination. Variations in vaccine products and their
administration, the health status of the animal, and the animal's genetic
predisposition to adverse events such as vaccine-associated feline sarcoma
may all contribute to the adverse event potential. In addition, an
animal's immune system response can vary because of factors including
their genetic makeup, interference from concurrent medications, stress,
parasitism, and other factors. Animals within a population, then, may fail
to respond to vaccines in a consistent and predictable pattern. COBTA
has completed a review of peer-reviewed literature and has assembled
consensus opinions from a wide spectrum of experts on vaccine use. These
comments should be regarded as representative of the best opinions
available and the current state of knowledge. It is acknowledged that
these opinions are not universally held by all experts, and that there are
insufficient data to authoritatively define the benefits and risks of all
vaccine products for the practitioner. Vaccine Use in Cats Feline
panleukopenia—Feline panleukopenia, caused by feline parvovirus, is
a potentially severe, life-threatening infectious disease. Inside and
outside cats are considered at high risk of exposure, because the virus
can survive sufficiently in the environment to be transported on clothing,
shoes, and other fomites. Although
vaccine brands may differ substantially, the efficacy of parenteral
modified-live and killed virus vaccines is generally considered high. The
efficacy of intranasal modified-live panleukopenia vaccines has been
questioned. The potential rate and severity of adverse events are
considered low to moderate with parenteral products. Caution should be
used with some modified-live virus (MLV) intranasal products used
in kittens under conditions of high density and high stress. Modified-live
products have not been shown to be safe in pregnant queens or in kittens
less than 1 month old. Maternal
antibody in most kittens decreases to a concentration that allows
successful immunization by 12 weeks of age. There is a growing body of
evidence that by following a successful kitten vaccination series and
revaccinating at 1 year of age, the subsequent revaccination interval can
be extended beyond 1 year. Feline
viral rhinotracheitis—Feline viral rhinotracheitis, caused by feline
herpesvirus-1 (FHV-1), is considered a potentially severe infectious
disease, but most infections result in mild clinical disease and
chronically infected carrier states. Risk of exposure is considered high
for cats in high-density environments. Husbandry is an extremely important
component for controlling this disease. Maternal
antibody generally decreases to a concentration that allows successful
immunization by 12 weeks of age. Topical vaccines are capable of
stimulating local immunity in the case of high maternal antibody
concentrations prior to 12 weeks of age. Although
vaccines differ, the efficacy of modified-live parenteral, modified-live
intranasal, and killed parenteral vaccines is considered to be high, but
successful vaccination often only decreases the severity of the clinical
disease and does not prevent infection or carrier states. Adverse
events include the possibility of creating carrier states with MLV vaccine
and signs of clinical disease from mucosal exposure to the MLV parenteral
products (licking injection sites). Intranasal MLV products are more
attenuated and less likely to cause clinical disease with mucosal exposure
than are the parenteral MLV products. Modified-live products have not been
shown to be safe in pregnant queens. There is a growing body of evidence
that by following a successful kitten vaccination series and revaccinating
at 1 year of age, the revaccination interval can be extended beyond 1
year. In
catteries that do not have occurrences of upper respiratory disease, the
use of killed vaccines is recommended, because they will limit acute
disease and will not introduce the attenuated vaccine virus into the
group. If FHV-1 is enzootic, it may be preferable to give MLV intranasal
vaccine, because it provides faster immunity and improved local immunity
and may be less likely to add to the infection problem than the MLV
parenteral product. Outbreaks
of FHV-1 infections spread rapidly, usually affecting all susceptible
animals in a colony within 2 weeks. During an outbreak involving only a
few sick cats, the use of MLV parenteral or intranasal products seems to
provide susceptible individuals with a subclinical infection and results
in more timely control. Feline
calicivirus infection—Calicivirus infection in cats usually results
in mild clinical disease and chronically infected carrier states, although
severe clinical disease is sometimes reported. Maternal antibody generally
decreases to a concentration that allows for successful immunization by 12
weeks of age. The protection from clinical disease afforded by calicivirus
vaccines appears to be variable and greatly influenced by the
heterogeneity of the caliciviruses that circulate in the cat population.
Calicivirus vaccines may only decrease the severity of the disease and not
prevent infection and carrier states. Vaccines that contain similar
antigens to the challenge organism generally provide better protection.
Duration of immunity studies on a small number of calicivirus challenges
with similar antigens suggest that, by following a successful kitten
vaccination series and revaccinating at 1 year, the revaccination interval
can be extended beyond 1 year. The duration of immunity when vaccines and
challenge antigens are dissimilar has not been well studied. Adverse
event rates appear to be higher for the modified-live calicivirus products
and include carrier states with clinical signs. Avoid mucosal exposure to
the MLV parenteral products (licking injection sites) as signs of disease
may result. Modified-live products have not been determined to be safe in
pregnant queens. The
impact of low-level or mild disease rates between vaccinates and
nonvaccinates appears low, but the use of MLV products may increase the
carrier rates in households with numerous cats. Killed vaccines do not
result in carrier states, and they prevent acute signs of the disease. Rabies—Rabies
virus represents a fatal risk to infected cats and people. In some areas
of North America rabies vaccination of cats is mandatory due to state or
local law, and in other areas it is discretionary. COBTA recognizes that
various regions of the United States have different vectors and
host-adapted rabies strains resulting in different risk issues for cats.
COBTA is encouraging the necessary discussions to re-evaluate the relative
risks and benefits of vaccination to cats, including any potential public
health impacts associated with discretionary vaccination against this
disease in regions with low risks. The AVMA Council on Public Health
continues to support mandatory rabies vaccination for all cats in North
America. Unlike
many other previously licensed biologics, rabies vaccines are tested to
determine their minimum duration of immunity. Local and regional
regulatory authorities mandate revaccination schedules including some that
are more frequent than necessary as demonstrated by scientific evidence. Feline
leukemia—Feline leukemia is a potentially severe life-threatening
infectious disease caused by the virus that bears the name of the disease;
however, risk of exposure is considered high only for those kittens that
come into close contact with viremic carrier cats, such as kittens that
live portions of their lives outside, and those maintained in high-density
feline environments with viremic carriers. The younger the kitten is at
exposure, the greater its chance of becoming permanently infected.
Susceptibility decreases with age, and kittens older than 16 weeks appear
to be resistant to infection on the basis of laboratory-based challenge
studies. Vaccines are labeled for use in kittens 9 weeks and older. It has
been difficult to experimentally infect cats older than 1 year without
first having severely depressed the immune system. Most older cats that
become infected will recover and not become chronic carriers. Control of
FeLV in controlled management conditions is best accomplished by testing
and elimination of carriers. Laboratory-based
comparisons of the efficacy of various FeLV vaccines have been highly
variable, and efficacy has been affected by the challenge models and
genetic background of the cats tested. Preventing exposure remains an
important control strategy. Veterinarians should carefully select the
brands of vaccine they use on the basis of scientific evidence. Screening
prevaccinates by ELISA and use of the indirect immunofluorescent antibody
test to confirm infection in cats are the recommended testing methods.
There is no known benefit to vaccinating cats infected with FeLV. Vaccination
is not recommended for cats with minimal to no risk of exposure,
especially after 4 months of age. If vaccination is deemed appropriate
because of a high-risk environment, most experts recommend annual
revaccination because of the difficulty in assessing age-related
resistance status. Chlamydiosis—Chlamydophilia
felis, formerly known as Chlamydia psittaci, causes
chlamydiosis and has variable virulence. A high risk of infection exists
in situations of high animal density and poor husbandry. The efficacy of
the vaccines in preventing disease or carrier states is considered poor,
and even though studies have demonstrated the ability of vaccines to lower
the severity of an infection, the degree of improvement provided through
vaccination is highly variable. Published references indicate a 1-year
duration of immunity, but most experts believe the duration of immunity is
considerably shorter. Chlamydophila
felis vaccines appear to be more likely to cause transitory fever and
lethargy than other feline vaccines. In addition, there appears to be more
likelihood of Chlamydophila felis vaccine involvement in mild
respiratory disease. Vaccination
is not recommended for cats with minimal or no risk of exposure. If
vaccination is deemed appropriate, annual revaccination appears
reasonable. In many management situations, control is better achieved by
hygiene and the control of other upper respiratory infections.
Antimicrobials are effective in controlling the clinical illness. Feline
infectious peritonitis—Feline coronavirus causes feline infectious
peritonitis. The vaccine has not been demonstrated to induce immunity in
kittens younger than 16 weeks old, and previous exposure to feline enteric
coronavirus usually results in neutralization of the MLV vaccine. Kittens
in shelters and catteries are considered to be at high risk but not likely
to benefit from vaccination, because enteric corona-virus infection is
enzootic in those kittens between 6 and 10 weeks of age. Dermatophytosis—Prevention
and control of M canis infection is complex in cats, especially in
multiple-cat households. The use of an integrated, multifaceted treatment
program is usually indicated. There are insufficient published data to
comment on the vaccine's clinical role in a control program. The vaccine
has not been demonstrated either to reduce the prevalence of infection or
to provide culture-negative cures. Bordetellosis—Efficacy
of the vaccine is considered low, and the duration of immunity is
considered short. Thus, the clinical value of this vaccine is
questionable. Deaths in litters from this disease have been reported to
occur prior to the approved age claim for the use of the vaccine. There
are no data on the use of the vaccine in younger cats. Some experts
expressed concern about the potential for adverse events associated with
vaccination of very young cats. Older cats have milder disease signs than
dogs and may not benefit substantially from vaccination. Giardiasis—Insufficient
information exists to comment. Feline
immunodeficiency virus infection—A vaccine against FIV was
introduced into the marketplace after the COBTA completed this report.
During the council's deliberations, neither published literature nor
expert panels assembled by COBTA addressed FIV vaccination in depth. This
new product is a whole-virus killed adjuvant vaccine. Its USDA approved
claim is "as an aid in the prevention of infection with feline
immunodeficiency virus." An issue for practitioners to consider in
the use of this product is that vaccinated cats will become seropositive,
as determined by the currently commercially available antibody-based
diagnostic tests. This may complicate existing testing guidelines and
disease control strategies. Vaccine Use in Dogs Canine
distemper—Canine distemper is a potentially severe, life-threatening
infectious disease with a high risk of exposure. Maternal antibody
generally decreases to a concentration that allows successful immunization
by 12 weeks of age. Although
vaccines differ, the efficacy of modified-live and recombinant parenteral
vaccines is considered high. The adverse event rate and severity potential
appear to be low, but includes postvaccinal encephalitis with some
vaccines. Some data indicate duration of immunity might be variable; there
is a growing body of evidence that, by following a puppy series and
revaccinating at 1 year, the subsequent revaccination interval can be
extended beyond 1 year. The recombinant product provides protection to 1
year, but there is insufficient experience to predict whether the
revaccination interval can be extended. Modified-live
virus vaccines are very temperature sensitive and must be stored within
product specifications, prior to and following reconstitution, to ensure
potency. Measles
vaccine—The measles vaccine has some indications for use in
high-risk distemper environments as a single IM injection in puppies
between 4 and 10 weeks of age where there is likely maternal antibody to
distemper. The modified-live parenteral product is highly efficacious in
protecting from disease but not infection. Adverse events are believed to
be infrequent. Vaccination of female puppies beyond 10 weeks of age
results in persistent antibody concentrations, which would be transferred
to future litters. These antibodies could interfere with response to the
measles vaccine should it be indicated for those litters. Early puppy
vaccination for measles should be followed by canine distemper
vaccination. Canine
parvovirus infection—Canine parvovirus causes a potentially severe
life-threatening infectious disease in dogs with a high risk of exposure.
Maternal antibody generally decreases to a concentration that allows
successful immunization by 12 weeks of age. Protection only occurs when
puppies are vaccinated after maternal antibody concentration is
sufficiently low to allow primary immunization. Because it takes about 2
weeks beyond the successful administration of the vaccine for a puppy to
adequately build protection, this period represents a window of
vulnerability. The
efficacy of modified-live parenteral vaccine is considered high. Because
there are only small differences between the 2, 2a, 2b, and 2c strains of
the virus, vaccines labeled to protect against 1 strain are expected to
protect against all 4 strains. Adverse event rates and severity are
considered low. Duration of immunity can vary considerably between
products. There is increasing evidence that, by following a puppy series
and revaccinating at 1 year, the subsequent revaccination interval can be
extended beyond 1 year. Neither mink enteritis nor heterotypic feline
panleukopenia virus vaccines are recommended for use in dogs. Hepatitis—Hepatitis,
caused by canine adenovirus type 1 (CAV-1), is a potentially
severe, life-threatening infectious disease with a high risk of exposure;
however, most infections do not result in severe disease. Maternal
antibody generally decreases to a concentration that allows successful
immunization by 12 weeks of age. Protection
for CAV-1 disease is obtained from the cross-protection associated with
CAV-2 vaccines. Because CAV-2 vaccines have been shown to have less
potential for adverse responses, only those vaccines containing CAV-2 are
recommended for use. Veterinarians are advised to look carefully at their
vaccines to identify whether they include CAV-1 or CAV-2 antigens.
Vaccines differ, but the efficacy of modified-live CAV-2 parenteral
vaccines is considered high. Adverse event rate and severity potential
appears to be low for CAV-2 products. Duration of immunity against
hepatitis is considered long. There is increasing evidence that by
following a puppy series and revaccinating at 1 year, the revaccination
interval can be extended beyond 1 year. Rabies—The
rabies virus represents a fatal risk to infected dogs and people. Rabies
in dogs has high potential for spreading to other dogs and is associated
with high risks of human exposure because of the infected dog's aggressive
behavior, frequent biting, and human interaction. Rabies vaccine is
recommended as a core vaccine in all dogs. The
efficacy of rabies vaccines is high. Adverse event rates are considered
low to moderate, with low-to-moderate severity. Unlike many other
previously licensed biologics, rabies vaccines are tested to determine
their minimum duration of immunity. Local and regional regulatory
differences impact the required revaccination intervals. Dogs would
benefit if the differences in required revaccination schedules between
regions were uniform and based on scientific data. Canine
adenovirus type 2 infection—Infection with CAV-2 can lead to
respiratory tract disease and may be 1 of many components of infectious
tracheobronchitis or kennel cough. Parenteral vaccines have been
demonstrated to provide long-term immunity against CAV-1 infection, but
expert opinions differ as to their ability to provide long-term protection
against the respiratory form (CAV-2). Modified-live intranasal vaccine
containing CAV-2 are now available, but their efficacy in preventing
clinical infectious tracheobronchitis has not yet been adequately studied.
The adverse events associated with these vaccines appear to be minimal.
Duration of immunity for the respiratory disease appears to be short.
Therefore, if vaccination against the respiratory form is warranted,
annual or more frequent revaccination may be necessary. Canine
parainfluenza—While the risk of exposure to the canine parainfluenza
virus is considered to be high, the virulence of this virus is low.
Vaccination is recommended only for dogs exposed to kennels, shelters, and
shows, and for dogs in large colonies or breeding establishments. The
efficacy of modified-live intranasal vaccines is considered moderate, and
that of parenteral MLV vaccine is considered low. Maternal antibody does
not interfere with immunity developed from MLV intranasal vaccine. Adverse
event rates are low, and duration of immunity is considered moderate.
Resistance to the natural disease develops with age. If vaccination is
deemed warranted, annual or more frequent revaccination may be necessary. Bordetellosis—The
risk of exposure to the causative agent is considered to be high in
kennel, shelter, show, and breeder groups, but virulence of the organism
is low. The efficacy of modified-live intranasal vaccines is considered to
be moderate, whereas that of parenteral vaccines is considered low.
Adverse event rates are low and include coughing, and duration of immunity
is considered short. Although
routine vaccination is not indicated, the use of an intranasal MLV product
about 2 weeks prior to exposure appears to have beneficial results. Leptospirosis—The
risk of exposure to various Leptospira serovars is regional,
generally seasonal, and impacted by the animal's lifestyle or purpose.
Virulence of the organism may be high, and the pathogen is zoonotic. The
efficacy of the bacterin is variable. A high percentage of animals
(perhaps 30%) may not respond to vaccination. The efficacy in those that
do respond is generally good. Possible vaccine variation between
manufacturers is not known. Adverse event rates are high and can be
severe. The duration of immunity is considered short. Because
there is no substantial cross protection between various Leptospira
serovars, new vaccines that contain those serovars most likely to cause
disease in dogs are needed. Canine
coronavirus infection—The risk of exposure to canine coronavirus is
considered to be high in kennel, shelter, show, and breeder dogs; however,
virulence of the virus is low. The efficacy of vaccines is considered low.
Adverse event rates are low. The duration of immunity is considered short. Borreliosis
(Lyme disease)—The risk of exposure to the causative agent is
considered to be low except in a few geographic locations with variable
virulence of the agent. Even in areas of high exposure, the incidence of
disease is low. The efficacy of the vaccine is believed to be limited to
previously unexposed dogs (ie, dogs without natural exposure to ticks
infected with Borrelia burgdorferi). Experts disagree whether the
vaccine is clinically effective. There is considerable speculation about
the potential of these vaccines to be involved in adverse events. Adverse
event rates are considered moderate. If vaccination is used, annual
revaccination is recommended. Giardiasis—Insufficient
information exists to comment. Serologic Tests COBTA's
review did not focus on serologic testing per se, but the council did
conclude that it is currently impossible to determine the immune status of
an animal relative to all the infectious diseases of concern without
conducting challenge testing. Further, serologic results do not appear to
be a sensitive indicator of immune response for some diseases or vaccines
in cats and dogs. It was concluded that there are variations within and
among laboratories, as well as a lack of validated sensitivity,
specificity, and confidence intervals, leading to the conclusion that
serologic testing is generally unreliable. It is noted that USDA licensing
of serologic tests does not require validation of this type. COBTA
agrees that higher serologic titers are generally associated with greater
resistance, but acknowledges it is possible for an animal with no titer
for a specific organism to have solid resistance to challenge. Conversely,
an animal with a titer that is generally regarded as protective for a
specific organism may also become ill as the result of challenge, possibly
because of overwhelming exposure or immune suppression. Advances
are being made in serologic testing methods, but practitioners are
cautioned to consider carefully whether the test proposed has been
appropriately validated, thereby providing a predictive value for whether
the animal needs to be revaccinated, and includes confidence intervals to
help the practitioner determine the risks and benefits of relying on the
test results. Practitioners should also determine whether a selected
laboratory has a quality control program sufficient to make the test
results reliable. Seeking More Practitioner Input The
AVMA wants to continue to provide vaccine information that practitioners
can use. Please share your ideas with any member of the council. Members
are listed on pages 1 and 2 of the AVMA 2002 Directory and Resource
Manual, or they can be contacted through our AVMA staff liaison, Dr.
Elizabeth Curry-Galvin, who can be reached at AVMA headquarters or by
e-mail (egalvin@avma.org). |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Drs.
Klingborg, Hustead, Curry-Galvin, Gumley, Henry, Bain, and Paul are
members of a COBTA working group on cat and dog vaccines; Drs. Boothe,
Blood, Huxsoll, Reynolds, Riddell, and Short are members of COBTA. Dr.
Reid is a former member of COBTA. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Originally posted on “BeyondVaccination” by H. Schmeck
|